MX2015016319A - Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas. - Google Patents

Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas.

Info

Publication number
MX2015016319A
MX2015016319A MX2015016319A MX2015016319A MX2015016319A MX 2015016319 A MX2015016319 A MX 2015016319A MX 2015016319 A MX2015016319 A MX 2015016319A MX 2015016319 A MX2015016319 A MX 2015016319A MX 2015016319 A MX2015016319 A MX 2015016319A
Authority
MX
Mexico
Prior art keywords
oxazolidinone
bacterial infections
quinolones
combination therapy
treating bacterial
Prior art date
Application number
MX2015016319A
Other languages
English (en)
Other versions
MX363678B (es
Inventor
Thomas Kapsner
Axel Dalhoff
Original Assignee
Morphochem Ag Für Kombina Torische Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphochem Ag Für Kombina Torische Chemie filed Critical Morphochem Ag Für Kombina Torische Chemie
Publication of MX2015016319A publication Critical patent/MX2015016319A/es
Publication of MX363678B publication Critical patent/MX363678B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención proporciona una combinación de al menos un híbrido de oxazolidinona-quinolona con al menos un compuesto antibacteriano adicional y el uso del mismo como fármaco, especialmente para el tratamiento o profilaxis de infecciones bacterianas.
MX2015016319A 2013-05-28 2014-05-28 Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas. MX363678B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13002761 2013-05-28
PCT/EP2014/001450 WO2014191109A1 (en) 2013-05-28 2014-05-28 Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections

Publications (2)

Publication Number Publication Date
MX2015016319A true MX2015016319A (es) 2016-06-02
MX363678B MX363678B (es) 2019-03-29

Family

ID=48536670

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016319A MX363678B (es) 2013-05-28 2014-05-28 Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.

Country Status (17)

Country Link
US (2) US9993469B2 (es)
EP (1) EP3003307B1 (es)
JP (1) JP6533780B2 (es)
KR (1) KR102242998B1 (es)
CN (1) CN105246476B (es)
AU (1) AU2014273471B2 (es)
BR (1) BR112015029367B1 (es)
CA (1) CA2912728C (es)
DK (1) DK3003307T3 (es)
ES (1) ES2838724T3 (es)
HK (1) HK1223305A1 (es)
IL (1) IL242770B (es)
MX (1) MX363678B (es)
NZ (1) NZ713946A (es)
RU (1) RU2675847C2 (es)
WO (1) WO2014191109A1 (es)
ZA (1) ZA201508325B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
DK2709619T3 (en) 2011-05-16 2018-01-15 Cellceutix Corp RELATIONSHIPS FOR USING THE TREATMENT OF MUCOSITIS
US9597319B2 (en) * 2014-04-23 2017-03-21 Case Western Reserve University Compositions and methods of inhibiting metallo-β-lactamases
LT3310331T (lt) * 2015-06-17 2021-01-11 Nabriva Therapeutics GmbH Švirkščiamos lefamulino farmacinės kompozicijos
US10751351B2 (en) * 2016-02-26 2020-08-25 Debiopharm International S.A. Medicament for treatment of diabetic foot infections
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
EP3560489A1 (en) * 2018-04-27 2019-10-30 European Molecular Biology Laboratory Pharmaceutical compositions for prevention and/or treatment of infections and antibacterial-induced dysfunctions
CN110563611B (zh) * 2019-09-19 2021-02-02 中国医学科学院医药生物技术研究所 一种异羟肟酸类衍生物及其制备方法和应用
CN111170911A (zh) * 2019-09-29 2020-05-19 安帝康（无锡）生物科技有限公司 用于治疗细菌感染性疾病的截短侧耳素类化合物
WO2021248008A1 (en) 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
RU2743922C1 (ru) * 2020-06-25 2021-03-01 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" 2'-Амино-2,5'-диоксо-5-фенил-1,2,5',6',7',8'-гексагидро-1'Н-спиро[пиррол-3,4'-хинолины]
CN116730870B (zh) * 2023-08-08 2023-10-13 中国医学科学院医药生物技术研究所 异羟肟酸类化合物或其可药用盐、及其用途和制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2424402A1 (en) 2000-12-21 2002-08-01 Pharmacia & Upjohn Company Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
ES2186550B2 (es) 2001-06-27 2003-11-16 Vita Lab Nuevos derivados de oxazolidinonas como antibacterianos.
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
CN100544719C (zh) * 2003-04-30 2009-09-30 莫弗凯姆联合化学股份公司 噁唑烷酮-喹啉杂化物抗生素用于制备治疗炭疽和其它感染的药物中的用途
JP4805139B2 (ja) * 2003-04-30 2011-11-02 モルホケム アクツィエンゲゼルシャフト フューア コンビナートリッシュ ヒェミー 炭疽および他の感染を治療するためのオキサゾリジノン‐キノリンハイブリッド抗生物質の使用
DE10340485B4 (de) 2003-09-03 2015-05-13 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Verfahren zur Herstellung von Oxazolidinon-Chinolon Hybriden
PT1709044E (pt) * 2003-12-18 2008-10-27 Morphochem Aktiengese Fur Komb Antibióticos híbridos de oxazolidinona-quinolona
AR054608A1 (es) 2005-08-08 2007-06-27 Actelion Pharmaceuticals Ltd Derivados de oxazolidinona enlazados a quinolonas como antibacterianos
DK2086968T3 (da) 2006-11-10 2012-03-19 Actelion Pharmaceuticals Ltd 5-hydroxymethyl-oxazolidin-2-on-derivater
CL2007003332A1 (es) 2006-11-24 2008-06-20 Actelion Pharmaceuticals Ltd Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
CN102014903B (zh) * 2008-05-09 2013-07-10 埃科特莱茵药品有限公司 用于治疗细菌性肠疾病的5-羟基甲基-*唑烷-2-酮衍生物
RU2371442C1 (ru) * 2008-06-30 2009-10-27 Государственное образовательное учреждение высшего профессионального образования "Южно-Российский государственный технический университет (Новочеркасский политехнический институт)" Способ получения 2-гетарилпроизводных бензотиазола и бензоксазола

Also Published As

Publication number Publication date
CA2912728A1 (en) 2014-12-04
RU2675847C2 (ru) 2018-12-25
NZ713946A (en) 2019-09-27
MX363678B (es) 2019-03-29
ZA201508325B (en) 2019-03-27
US20190111046A1 (en) 2019-04-18
ES2838724T3 (es) 2021-07-02
CN105246476B (zh) 2019-11-15
JP2016523854A (ja) 2016-08-12
WO2014191109A1 (en) 2014-12-04
KR20160013192A (ko) 2016-02-03
US9993469B2 (en) 2018-06-12
AU2014273471B2 (en) 2019-10-03
EP3003307B1 (en) 2020-11-11
JP6533780B2 (ja) 2019-06-19
KR102242998B1 (ko) 2021-04-21
RU2015155646A (ru) 2017-07-04
BR112015029367B1 (pt) 2022-08-23
RU2015155646A3 (es) 2018-04-28
BR112015029367A8 (pt) 2020-03-17
DK3003307T3 (da) 2020-12-14
IL242770B (en) 2020-10-29
EP3003307A1 (en) 2016-04-13
CN105246476A (zh) 2016-01-13
CA2912728C (en) 2021-04-13
BR112015029367A2 (pt) 2017-07-25
AU2014273471A1 (en) 2015-12-17
HK1223305A1 (zh) 2017-07-28
US20160113921A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
MX2015016319A (es) Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas.
PH12017502298A1 (en) Antibacterial compounds
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
PH12016500207A1 (en) Anti-infective compounds
MX2016009898A (es) Tratamientos para acne resistente.
NZ713621A (en) Compounds and methods of treating infections
WO2015003816A3 (en) Cystobactamides
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
MX366481B (es) Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
PH12016500453A1 (en) Antimicrobial compounds and methods of making and using the same
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
MX2016009248A (es) Compuestos que contienen nitrogeno y su uso como agentes antibacterianos.
PH12017501741A1 (en) Histamine-producing bacterial strains and their use in cancer
MX2015008486A (es) Composiciones y metodos para tratar infecciones bacterianas.
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX364443B (es) Agentes antimicrobianos.
IN2013MU03216A (es)
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
TN2015000409A1 (en) Rifaximin for use in the treating of vaginal infections
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2015009505A (es) Actividad antimicrobiana "in vitro" de la combinacion de peptidos antibiocidas de alacran con antibioticos de uso comun.
UA91618U (uk) Антимікробний засіб паммосепт плюс